搜尋結果

共 207 個結果
頁數:1...3 4 5 6 7 8 9 10 11

3 hep B vaccine makers told to stop output, paper says

... g Tiantan Biological Products Co. Ltd. (600161.CN), Shenzhen Kangtai Biological Products Co. Ltd. and Dalian Hissen Bio-pharm Inc. Makers of blood products, vaccines and injection products had until T ...More

EJ Insight2014-01-02

5 firms get IPO nod as listings to resume, Bloomberg says

... ang Wolwo Bio-Pharmaceutical said they received approvals for initial share sales. About 50 companies are expected to complete the IPO approval preparations and list or be ready to do so by the end of ...More

EJ Insight2013-12-31

Three firms said to be caught up in vaccine scare, paper says

... n Kangtai Biological Products Co. Ltd., while three other babies' deaths may be linked to vaccines produced by Beijing Tiantan Biological Products Co. Ltd. (600161.CN), the report said. Another case, ...More

EJ Insight2013-12-26

HKEJ Today: Highlights

...  Cho says Bio-technology and medical counters are likely to outperform other stocks in the coming year, said HKEJ chief consultant Cho Chi-ming. Given an aging population in China, the healthcare sect ...More

EJ Insight2013-12-18

POLICY WATCH: Shanghai smog adds new urgency to pollution fight

... nergy and bio-fuels, as well as control the use of coal, the NDRC said. All new projects are required to meet energy-saving targets. In other initiatives, authorities will study the possibility of est ...More

EJ Insight2013-12-13

Hua Han FY profit down 66.1% at HK$223 mln, filing says

Hua Han Bio-Pharmaceutical Holdings Ltd. (00587.HK) said in a regulatory filing on Tuesday its net profit for the fiscal year to June dropped 66.1 percent to HK$223 million (US$28.75 million) from a y ...More

EJ Insight2013-10-02

Top leaders in group study at Beijing hi-tech park, Xinhua says

... aterials, bio-chips and precise crop breeding, it said. -- Contact HKEJ [email protected] SK/RC   ...More

EJ Insight2013-10-02

頁數:1...3 4 5 6 7 8 9 10 11

信報簡介 | 服務條款 | 私隱條款 | 免責聲明 | 廣告查詢 | 加入信報 | 聯絡信報

股票及指數資料由財經智珠網有限公司提供。期貨指數資料由天滙財經有限公司提供。外滙及黃金報價由路透社提供。

本網站的內容概不構成任何投資意見,本網站內容亦並非就任何個別投資者的特定投資目標、財務狀況及個別需要而編製。投資者不應只按本網站內容進行投資。在作出任何投資決定前,投資者應考慮產品的特點、其本身的投資目標、可承受的風險程度及其他因素,並適當地尋求獨立的財務及專業意見。本網站及其資訊供應商竭力提供準確而可靠的資料,但並不保證資料絕對無誤,資料如有錯漏而令閣下蒙受損失,本公司概不負責。